DRTE Dendrite International (MM)

Dendrite International, Inc. (NASDAQ: DRTE) announced today three contract signings in Japan to expand its leadership position for sales force effectiveness solutions in the world�s second largest pharmaceutical market. One international and two Japanese domestic pharmaceutical companies are adopting Dendrite�s j-forceNET�, a Web-based sales force effectiveness solution for sales representatives, field managers, and home office staff in Japan. Two of the companies also will implement Dendrite�s new j-forceWIRELESS� system, a mobile-phone solution fully integrated with j-forceNET to further increase the mobility of its sales representatives. Today�s announcement involves 860 sales representatives, which boosts the total number in Japan using Dendrite solutions to more than 25,000, a market share exceeding 40%. j-forceNET integrates all necessary sales and support functions in a single system. Designed specifically for the Asian pharmaceutical market, the solution enables companies to manage all aspects of customer relationships, which includes viewing sales data, entering customer activity information, updating client profiles, accessing corporate resources, and effectively communicating with the home office. The addition of j-forceWIRELESS allows sales representatives to use mobile phones to review and input urgent information, which ensures a quicker response to their customers. �Our success with the j-forceNET solution continues throughout Asia, and the new j-forceWIRELESS platform allows the mobile sales force to access critical customer data anytime and anywhere,� said Jean-Paul Modde, President, Dendrite Asia Pacific. �With the advances in mobile and wireless technology across the Asian region, we are seeing an increased level of interest from pharmaceutical companies to deploy solutions on these highly cost- effective devices.� About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The company has clients in more than 50 countries and includes the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.